# Efgartigimod ph20 sc PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/efgartigimod-ph20-sc

> The next catalyst for efgartigimod ph20 sc, sponsored by ARGENX SE (ARGX), is its primary completion, March 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | efgartigimod ph20 sc |
| Codes | PH20, ARGX-113 |
| Sponsor | ARGENX SE (ARGX) https://sec-api.dev/companies/argx/catalysts |
| Indications | [Primary Immune Thrombocytopenia](https://sec-api.dev/indications/primary-immune-thrombocytopenia), Sjogrens Disease, Myasthenia Gravis, Ocular, [Myositis](https://sec-api.dev/indications/myositis), [Generalized Myasthenia Gravis](https://sec-api.dev/indications/generalized-myasthenia-gravis), [Thyroid Eye Disease](https://sec-api.dev/indications/thyroid-eye-disease), [Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)](https://sec-api.dev/indications/chronic-inflammatory-demyelinating-polyneuropathy-cidp), [Primary Sjogrens Disease](https://sec-api.dev/indications/primary-sjogrens-disease), [Graves' Disease](https://sec-api.dev/indications/graves-disease), [Graves Disease](https://sec-api.dev/indications/graves-disease), [Systemic Sclerosis (SSc)](https://sec-api.dev/indications/systemic-sclerosis-ssc) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### December 15, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Thyroid Eye Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06307613 (A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06307613

### December 15, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Thyroid Eye Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06307626 (A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06307626

### January 12, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Myasthenia Gravis, Ocular.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06558279 (A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06558279

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Systemic Sclerosis (SSc).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06655155 (A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06655155

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Systemic Sclerosis (SSc).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06655155 (A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06655155

### Apr to Jul 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04280718 (A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT04280718

### April 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04280718 (A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT04280718

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Primary Sjogrens Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06684847 (A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06684847

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Primary Sjogrens Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06684847 (A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06684847

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Generalized Myasthenia Gravis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06392386 (A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06392386

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Generalized Myasthenia Gravis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06392386 (A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06392386

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Primary Immune Thrombocytopenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04812925 (A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT04812925

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Primary Immune Thrombocytopenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04812925 (A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT04812925

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Graves' Disease; Graves Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07570316 (A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT07570316

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Graves' Disease; Graves Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07570316 (A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT07570316

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Graves Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07596849 (A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT07596849

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Graves Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07596849 (A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT07596849

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Sjogrens Disease; Primary Sjögren's Syndrome Painful Sensory Neuropathies.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07760818 (A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-07-28 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT07760818

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Sjogrens Disease; Primary Sjögren's Syndrome Painful Sensory Neuropathies.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07760818 (A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-07-28 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT07760818

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Myositis; Active Idiopathic Inflammatory Myopathy; Dermatomyositis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05979441 (A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT05979441

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Myositis; Active Idiopathic Inflammatory Myopathy; Dermatomyositis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05979441 (A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT05979441

## Same indication

- [ALXN1720](https://sec-api.dev/pdufa/alxn1720) (AZN)
- [AMG-732](https://sec-api.dev/pdufa/amg-732) (AMGN)
- [MoDE (BHV-1300)](https://sec-api.dev/pdufa/bhv-1300) (BHVN)
- [VYVGART (efgartigimod)](https://sec-api.dev/pdufa/efgartigimod) (ARGX)
- [Efgartigimod iv](https://sec-api.dev/pdufa/efgartigimod-iv) (ARGX)
- [Efgartigimod iv or efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-iv-or-efgartigimod-ph20-sc) (ARGX)
- [Experimental: yb-101](https://sec-api.dev/pdufa/experimental-yb-101) (YARW)
- [Felzartamab](https://sec-api.dev/pdufa/felzartamab) (BIIB)
- [Gefurulimab](https://sec-api.dev/pdufa/gefurulimab) (AZN)
- [Ianalumab](https://sec-api.dev/pdufa/ianalumab) (NVS)
- [Imvt-1401 (batoclimab)](https://sec-api.dev/pdufa/imvt-1401-batoclimab) (IMVT)
- [IMVT-1402](https://sec-api.dev/pdufa/imvt-1402) (IMVT)
- [FABHALTA® (iptacopan)](https://sec-api.dev/pdufa/iptacopan) (NVS)
- [IMAAVY (nipocalimab)](https://sec-api.dev/pdufa/nipocalimab) (JNJ)
- [PF-06823859](https://sec-api.dev/pdufa/pf-06823859) (PFE)
- [PF-06835375](https://sec-api.dev/pdufa/pf-06835375) (PFE)
- [Pozelimab + cemdisiran](https://sec-api.dev/pdufa/pozelimab-cemdisiran) (REGN)
- [Ultomiris® (ravulizumab)](https://sec-api.dev/pdufa/ravulizumab) (AZN)
- [Remibrutinib (blinded)](https://sec-api.dev/pdufa/remibrutinib-blinded) (NVS)
- [Wayrilz (rilzabrutinib)](https://sec-api.dev/pdufa/rilzabrutinib) (SNY)
- [Nplate (romiplostim)](https://sec-api.dev/pdufa/romiplostim) (AMGN)
- [APRIL (telitacicept)](https://sec-api.dev/pdufa/telitacicept) (VOR)
- [TEPEZZA® (teprotumumab)](https://sec-api.dev/pdufa/teprotumumab) (AMGN)
- [APPROACH (tibulizumab)](https://sec-api.dev/pdufa/tibulizumab) (ZURA)
- [VRDN-003](https://sec-api.dev/pdufa/vrdn-003) (VRDN)

Calendar months: [April 2027](https://sec-api.dev/fda-calendar/2027-04), [July 2028](https://sec-api.dev/fda-calendar/2028-07)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/efgartigimod-ph20-sc.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Efgartigimod ph20 sc PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/efgartigimod-ph20-sc

```bibtex
@misc{secapidev_pdufa_efgartigimod_ph20_sc_20261116,
  title        = {Efgartigimod ph20 sc PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/efgartigimod-ph20-sc}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_efgartigimod_ph20_sc_20261116","title":"Efgartigimod ph20 sc PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/efgartigimod-ph20-sc","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
